Salvador Escorza

GI Oncologist | Internal Medicine | Professional Stoic | INTJ | Opinions my own

[Arndt Vogel @ArndtVogel]

👏Standing ovations for Daraxonrasib👏
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic cancer: Primary and final analysis from the phase-3 RASolute 302 study
👉mPFS 7.6 vs 3.5 mo
👉mOS: 13.2 vs 6.6 mo
👏Fantastic news, new standard of care
@myesmo @ASCO

[NEJM @NEJM]

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: https://t.co/LBqROGlouc

Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://t.co/5Ox6Kuax6Q

[Arndt Vogel @ArndtVogel]

Fulminant Tumour Lysis Syndrome after Nivolumab and Ipilimumab treatment for Hepatocellular Carcinoma
@JHepatology
https://t.co/4IXJjeXSps
🧐New problems with more effective systemic therapies in HCC❗️
@myESMO @EASLedu @ILCAnews

[Salvador Escorza @Escorzza]

Trust…

…But double check

[Jeremiroquai @Jerematic79]

My oncologist tried to stop my chemotherapy* treatment last week because of a one-page synopsis he had read regarding my recent MRI, which mentioned that one of my brain tumors had progressed.

It turns out he had never actually looked at the MRI itself; and the specialist who wrote the synopsis had not actually compared the new images to my previous MRI from 2024.

I was skeptical, as my symptoms had not progressed; so I asked my oncologist to show me a comparison of the two most recent MRIs, to demonstrate the growth. So, he brought them up on his screen and showed me a clear difference between image on the left and one on the right.

"But the one on the left is the 2017 MRI," I said. "We both know the tumor has grown since then."

The doctor was surprised, and said, "You're right. I'm not sure why the 2024 MRI isn't showing up."

Anyway, we had to go to a different room and use a different computer to find last year's images. When my oncologist finally brought them up, he realized there was a clear REDUCTION in the size of my tumor, as well as a loss of contrast, indicating that the tumor was dying. So, the chemotherapy was working after all!

Had I taken my doctor at his word, and stopped my chemotherapy, I would have soon needed an extremely risky brain surgery that would have changed my life forever.

We are living through a crisis of competence in America — or is it in the world as a whole? It is absolutely essential that we remain vigilant and look out for our own health, because we apparently can no longer trust our doctors to do it for us. Remember to ask questions, get second opinions and, above all, don't just assume that your doctor is infallible. Now more than ever, your life is in your own hands.

[Salvador Escorza @Escorzza]

** * CURSO * * *
1er Curso Carcinoma Hepatocelular
4 y 5 de octubre
Informes: [email protected]
Registro: https://t.co/X4v4p7Ej0Z

[Salvador Escorza @Escorzza]

@EvelynBeas2 @INCMNSZ_Uronco So proud of you!!! Congrats!

[Salvador Escorza @Escorzza]

@RZubiranS @nih_nhlbi @TheBethesdaLabs Que orgullo amigo, muchas felicidades!

[Salvador Escorza @Escorzza]

Very excited to join the GI oncology team at @MSKCancerCenter as an observer for this month. Special thanks to @GABOUALFA and @SMEOMX for the opportunity

[NEJM @NEJM]

Original Article: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC (FLAURA2 phase 3 trial) https://t.co/INs1SjDyH2

Editorial: Combination Therapy for EGFR-Mutated Lung Cancer https://t.co/paGyrA40o8

#oncology

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#ESMO23 #pNET 🦓
📣LBA53 ph3 CABINET
Dr Jennifer Chan @ALLIANCE_org
➡️ 2:1 Cabozantanib v placebo in pre-treated (>=1 prior line) #epNET (n=197) and #pNET (n=93)
📌 Primary endpoint PFS
✅ epNET HR 0.45 mPFS 8.2v 3.2m
✅ pNET HR 0.27 11.4v 3m
✅ ORR epNET 4% pNET 18%
☢️ HTN, fatigue, HFS
🔸 OS not sig but delta of 12m in pNET
➡️ new option for pre-treated progressing NETs
@OncoAlert @CNETSCanada @NANETS1 @myESMO

[Salvador Escorza @Escorzza]

Proud to present our work on Delay in pancreatic cancer diagnosis & treatment at #WCGIC2023 @DraVanessaRC @MoniquMeneses #ESMOGI @incmnszmx

[Salvador Escorza @Escorzza]

Stop by at ASCO 2023 for our work with @DraVanessaRC on germline mutations in pancreatic cancer

[Vanessa RC @DraVanessaRC]

Happy to present our work on behalf my co-investigators @ASCO #ASCO23 @Escorzza @incmnszmx @INCMNSZ_Ensena @incanMX @ABCcentromedico 🧬 #PancreaticCancer 💜🇲🇽

[Salvador Escorza @Escorzza]

@RZubiranS Ya siempre los mando a dislipidemias

[Salvador Escorza @Escorzza]

@sandydamus Desconocer el manejo (o diagnóstico) no es criterio para ofrecer cuidados paliativos.

[Salvador Escorza @Escorzza]

@iandresmeraz @hafaydeefe Si supiera que eres fan del panda…

[Salvador Escorza @Escorzza]

Our poster at @CharityAMMF

Thanks to @DraVanessaRC @alejandrogath @incmnszmx

[Raúl Mellado-Orellana @melladoorellana]

Today we had the opportunity to exchange views on renal cancer with @drenriquegrande and different residents from other cancer centers! @incanMX @medicasur @incmnszmx thank you! @BourlonMaite

[Santiesteban @s_santiesteban]

🔴DESTINY-Breast trials investigating trastuzumab deruxtecan (T-DXd) #bcsm

[Oncology Brothers @OncBrothers]

#DESTINYBreast03 Ph3, N=524, 2L, TDXd vs trast emtansine, Her2 +ve mBC

- HR for progression 0.28
- HR for death 0.55
- ORR ~80% Vs ~34%
- Grade 3/4 AEs 45% Vs 40%
- Pneumonitis/ILD 10.5% (no Gr 4/5)

#MedTwitter @OncoAlert #BCSM #OncED #PracticeChanging @JavierCortesMD @NEJM